Physician profile
Peter Duros
NPI 1669498119
$7,661.21
in general payments reported to CMS, 2019-2025
56 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $265 · 2021: $592 · 2022: $1,394 · 2023: $1,390 · 2024: $1,343 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,995.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,405.82 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $613.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.37 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Mylan Specialty L.P. | $428.67 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $427.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $393.48 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $341.06 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $313.98 | 2021-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $212.62 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.83 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $203.58 | 2019-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $187.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $176.52 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $175.94 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $162.51 | 2019-2025 | Rexulti, Abilify Maintena |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Duros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.